NCT00090298已完成3 期
A Multicenter, Randomized, Double-Blind Study to Evaluate the Lipid-Altering Efficacy and Safety of the Ezetimibe/Simvastatin Combination Tablet Versus Rosuvastatin in Patients With Primary Hypercholesterolemia
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 2,815
- 主要终点
- LDL-C lowering efficacy after 6 weeks.
研究概览
简要总结
A 10-week study to compare the reduction in cholesterol following treatment with two different marketed drugs in patients with hypercholesterolemia.
详细描述
The duration of treatment is 6 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 69 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
LDL-C lowering efficacy after 6 weeks.
次要结局
- Safety;changes in TC, non-HDL-C, TG, HDL-C, Apo B, LDL-C/HCL-C ratio.
研究者
相似试验
已完成
3 期
A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)Type 2 Diabetes MellitusHypercholesterolemiaNCT00110435Organon and Co1,229
已完成
3 期
Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)HypercholesterolemiaNCT00092586Organon and Co2,904
已完成
2 期
Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol LevelsHyperlipidemiasNCT00813527Takeda213
已完成
3 期
Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)Mixed HyperlipidemiaNCT00289900Merck Sharp & Dohme LLC2,340
已完成
3 期
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)Coronary DiseaseHypercholesterolemiaNCT00092625Organon and Co442